Date: 2016-12-22
Type of information: Licensing agreement
Compound: MM-II
Company: Sun Pharmaceutical Industries (India) Moebius Medical (Israel)
Therapeutic area: Inflammatory diseases - Rheumatic diseases
Type agreement: licensing
Action mechanism:
- biolubricant. MM-II is a novel non-opioid product that leverages the physical properties of proprietary liposomes to lubricate arthritic knee joints, thereby reducing friction and wear, consequently leading to joint pain reduction.
This intra-articular biolubricant injection is being developed to provide symptomatic relief of mild-to-moderate osteoarthritis pain. It is based on patent-protected technology licensed by Moebius Medical from the Hebrew University of Jerusalem, Technion Israel Institute of Technology and Hadassah Medical Centre.
Disease: pain in osteoarthritis
Details:
- • On December 12, 2016, Sun Pharmaceutical Industries and Moebius Medical have entered into an exclusive worldwide licensing deal to further develop MM-II, a novel pharmaceutical candidate for the treatment of pain in osteoarthritis. This agreement will support Sun Pharma's efforts to build a branded product pipeline and to enrich its portfolio for pain products. To date, Moebius Medical has completed a first-in-man clinical study at Hadassah Medical Center, demonstrating the product’s fast onset of action and its potentially better efficacy and comparable safety for alleviating osteoarthritis pain as compared to hyaluronic acid injection.
- Moebius Medical will conduct requisite pre-clinical studies, and will assume responsibility for product development and manufacturing through the end of Phase-II studies. Sun Pharma will assume responsibility for further clinical studies, regulatory submissions and product commercialization.
Financial terms:
- According to the agreement, Sun Pharma will fund further development of Moebius Medical’s lead product, MM-II, and undertake its global commercialization. Moebius Medical will receive an upfront payment, development-based and
sales-based milestone payments, and tiered royalties on sales from Sun Pharma.
Latest news:
Is general: Yes
